After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...

Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...

Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

The lawsuit claims the FDA's finding that there was no longer a shortage of the drugs' active ingredient semaglutide was ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

With Novo Nordisk’s blockbuster drugs Wegovy and Ozempic back in stock, copycat versions of semaglutide are no longer allowed ...

This will be a “pivotal year,” one expert says, for GLP-1 drugs, which are massively disrupting the benefits landscape.

The shortage of Ozempic and Wegovy has been declared over by the Food and Drug Administration, a change that suggests higher ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...